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Preferred Reporting Items for a Systematic Review
andMeta-analysis of Individual Participant Data
The PRISMA-IPD Statement
Lesley A. Stewart, PhD; Mike Clarke, DPhil; Maroeska Rovers, PhD; Richard D. Riley, PhD; Mark Simmonds, PhD;
Gavin Stewart, PhD; Jayne F. Tierney, PhD; for the PRISMA-IPD Development Group
IMPORTANCE Systematic reviews andmeta-analyses of individual participant data (IPD) aim
to collect, check, and reanalyze individual-level data from all studies addressing a particular
research question and are therefore considered a gold standard approach to evidence
synthesis. They are likely to be used with increasing frequency as current initiatives to share
clinical trial data gain momentum andmay be particularly important in reviewing
controversial therapeutic areas.
OBJECTIVE To develop PRISMA-IPD as a stand-alone extension to the PRISMA (Preferred
Reporting Items for Systematic Reviews andMeta-Analyses) Statement, tailored to the
specific requirements of reporting systematic reviews andmeta-analyses of IPD. Although
developed primarily for reviews of randomized trials, many items will apply in other contexts,
including reviews of diagnosis and prognosis.
DESIGN Development of PRISMA-IPD followed the EQUATOR Network framework guidance
and used the existing standard PRISMA Statement as a starting point to draft additional
relevant material. A web-based survey informed discussion at an international workshop that
included researchers, clinicians, methodologists experienced in conducting systematic
reviews andmeta-analyses of IPD, and journal editors. The statement was drafted and
iterative refinements were made by the project, advisory, and development groups. The
PRISMA-IPD Development Group reached agreement on the PRISMA-IPD checklist and flow
diagram by consensus.
FINDINGS Compared with standard PRISMA, the PRISMA-IPD checklist includes 3 new items
that address (1) methods of checking the integrity of the IPD (such as pattern of
randomization, data consistency, baseline imbalance, andmissing data), (2) reporting any
important issues that emerge, and (3) exploring variation (such as whether certain types of
individual benefit more from the intervention than others). A further additional itemwas
created by reorganization of standard PRISMA items relating to interpreting results. Wording
wasmodified in 23 items to reflect the IPD approach.
CONCLUSIONS AND RELEVANCE PRISMA-IPD provides guidelines for reporting systematic
reviews andmeta-analyses of IPD.
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S ystematic reviews and meta-analyses of individual partici-pant data (IPD) aim to identify, appraise, and summarizethe evidence from multiple studies addressing the same
research question or topic. Unlike most systematic reviews, they
do not rely on aggregate data extracted from journal publications.
Rather, the original data on each individual participant are
sought from each eligible study. These data typically include char-
acteristics such as age or stage of disease, the intervention or
exposure being investigated, and follow-up data on outcomes
and events.
“Participant” isusedtodescribetheunitofanalysisbecausemost
commonly this is an individualperson.However, itmayapplyequally
to other units of analysis, such as a school, primary care practice, or
hospital inacluster randomizedtrial,oran individualbodypart.What
is important is the availability of raw unit-level data rather than ag-
gregate-level data extracted from a report.
The PRISMA (Preferred Reporting Items for Systematic Re-
viewsandMeta-Analyses) Statementpublished in2009,1which in-
cludes a 27-item checklist and flowdiagram,was developed princi-
pally for systematic reviewsandmeta-analysesof randomized trials
that use aggregate data, generally extracted from published re-
ports. It thereforedoesnotcover some importantaspectsof the IPD
approach to systematic review and meta-analysis, particularly the
methodsusedtoobtain,check,andsynthesizethe IPD,andtohandle
studies for which IPD were not available. PRISMA-IPD was devel-
oped to address these issues.
Methods
PRISMA-IPD was developed based on the methodological frame-
work for guideline development published by the EQUATOR
Network.2 The standard PRISMAStatement1was used as a starting
point, and initial work to adapt and build on this was led by a steer-
ing group aided by a small project group.
The project group conducted a review of how systematic
reviews and IPD meta-analyses are currently reported to update
previous evaluations and guidance in this area.3,4 An initial draft
adaptation of the standard PRISMA checklist was then prepared
by the steering and project groups. This formed the basis of an
electronic questionnaire distributed to 95 members of the Coch-
rane IPD Meta-analysis Methods Group, 88 members of the Soci-
ety for Research Synthesis Methods, 4 members of both, and 4
additional individuals invited to help develop the extension.
Recipients were asked to send the questionnaire to others who
might be interested. Links to the survey were placed on the web-
sites of the Cochrane IPD Meta-analysis Methods Group, the Cen-
tre for Reviews and Dissemination (CRD), and the Systematic
Reviews journal, as well as on the Cochrane Facebook page. The
CRD also advertised the survey using Twitter. The survey remained
open for 14 days.
The questionnaire sought feedback on the appropriateness of
standard PRISMA Statement items to IPD and on suggested
changes and additions. It included 4 items with suggested word-
ing changes (1, 3, 6, 18), 8 items with additional proposed ele-
ments (11, 14, 15, 16, 17, 19, 20, 25), and 1 item with both (10). Pro-
posed wording changes were rated “appropriate” or “other change
required,” and suggested additional components were rated as
“not required,” “possible,” “desirable,” or “essential.” Fourteen
items had no suggested changes at that stage (2, 4, 5, 7, 8, 9, 12, 13,
21, 22, 23, 24, 26, 27).
A 1-day international workshop was convened in York, United
Kingdom, in March 2013. The 26 participants included systematic
reviewerswithexperience in IPDsynthesis (n = 21), clinicians (n = 6),
methodologists (n = 20), and journal editors (n = 10). Survey feed-
backwas presented, and eachPRISMA itemwasdiscussed in detail
andagreementon inclusionandwording reachedbyconsensus.The
checklist preparedduring theworkshopwas thencirculated for fur-
ther comment to participants and to 3 people unable to attend. It
continued to be refined iteratively by the steering group and sub-
sequently the wider development group.
Results
Survey Response
Fifty-three responses to the questionnaire were received, a 28%
response rate based on direct invitations (numbers of respon-
dents not invited directly are unknown). Of 38 respondents who
answered demographic questions, there were 28 systematic
reviewers, 9 health care practitioners, 1 policy maker, 27 method-
ologists, 13 statisticians, and 3 publishers. Twenty-seven reported
membership of the Cochrane Collaboration and 11 indicated that
they were not members. Twelve reported no practical experience
with IPD systematic reviews, whereas 5 had completed 1, 10 had
completed between 2 and 5, and 11 had completed more than 5
such reviews.
Respondentssupportedsuggestedwordingchanges for4 items
(>80%scoredasappropriate)andrequired furtherchange for 1 item
(31% scored as appropriate). Suggested additions concerning data
checking,prespecification,statisticalanalysis, studyvariablessought,
numbers of participants, IPD-based description of clinical charac-
teristics, reasons fornonprovisionof IPD,howstudieswithandwith-
out IPDwere analyzed together, and the effect of unavailable trials
andmissing IPDwere supported (>70%). Providingparticular data-
checkingdetails andproductionof forest plots for all analyseswere
not supported (<70%). These results were used only as a starting
point for deliberation at the workshop.
Workshop Response
At the workshop 25 checklist items were modified during discus-
sion, much of which centered on striking a balance between being
consistentwith the standardPRISMAStatementandcoveringall as-
pects of reporting pertinent to IPD. Iterative modification and re-
finement of almost all items by the steering and wider develop-
ment groups continued until September 2014.
Final PRISMA-IPD Checklist
The Table presents the final PRISMA-IPD checklist adapted and
extended from the original PRISMA Statement, as agreed by con-
sensus of those involved in its development. This includes provi-
sion for additional information required to describe adequately
the IPD approach or where some rewording provides clarity, par-
ticularly in the context of IPD. PRISMA-IPD contains 23 items in
which the wording has been modified and 3 new items on meth-
ods of checking data integrity (A1), on methods of exploring varia-
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tion (A2), and on reporting any important issues identified as a
result of data checking (A3). The other additional item (A4) has
been created as a consequence of rearranging items relating to
interpretation of results.
To clarify differences, eTable 1 in the Supplement presents
the PRISMA and PRISMA-IPD checklists side by side. eTable 2 in
the Supplement provides examples from previously published
work illustrating how reports may be suitably worded. The Figure
presents a modified version of the PRISMA flow diagram, which
may also be downloaded from the PRISMA (http://www.prisma
-statement.org) and EQUATOR (http://www.equator-network
.org) websites, as may the checklist.
Table. PRISMA-IPD Checklist of Items to IncludeWhen Reporting a Systematic Review andMeta-analysis of Individual Participant Data (IPD)a
PRISMA-IPD
Section/Topic
Item
No.b Checklist Item Reported on Page
Title
Title 1 Identify the report as a systematic review and meta-analysis of individual participant data.
Abstract
Structured summary 2 Provide a structured summary including as applicable:
Background: state research question and main objectives, with information on participants,
interventions, comparators, and outcomes.
Methods: report eligibility criteria; data sources including dates of last bibliographic search or
elicitation, noting that IPD were sought; methods of assessing risk of bias.
Results: provide number and type of studies and participants identified and number (%) obtained;
summary effect estimates for main outcomes (benefits and harms) with confidence intervals and
measures of statistical heterogeneity. Describe the direction and size of summary effects in terms
meaningful to those who would put findings into practice.
Discussion: state main strengths and limitations of the evidence, general interpretation of the results,
and any important implications.
Other: report primary funding source, registration number, and registry name for the systematic
review and IPD meta-analysis.
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known.
Objectives 4 Provide an explicit statement of the questions being addressed with reference, as applicable, to
participants, interventions, comparisons, outcomes, and study design (PICOS). Include any hypotheses
that relate to particular types of participant-level subgroups.
Methods
Protocol and
registration
5 Indicate if a protocol exists and where it can be accessed. If available, provide registration information
including registration number and registry name. Provide publication details, if applicable.
Eligibility criteria 6 Specify inclusion and exclusion criteria including those relating to participants, interventions,
comparisons, outcomes, study design, and characteristics (eg, years when conducted, required
minimum follow-up). Note whether these were applied at the study or individual level, ie, whether
eligible participants were included (and ineligible participants excluded) from a study that included a
wider population than specified by the review inclusion criteria. The rationale for criteria should be
stated.
Identifying
studies—information
sources
7 Describe all methods of identifying published and unpublished studies including, as applicable: which
bibliographic databases were searched with dates of coverage; details of any hand searching including
of conference proceedings; use of study registers and agency or company databases; contact with the
original research team and experts in the field; open advertisements; and surveys. Give the date of last
search or elicitation.
Identifying
studies—search
8 Present the full electronic search strategy for at least 1 database, including any limits used, such that
it could be repeated.
Study selection
processes
9 State the process for determining which studies were eligible for inclusion.
Data collection
processes
10 Describe how IPD were requested, collected, and managed, including any processes for querying and
confirming data with investigators. If IPD were not sought from any eligible study, the reason for this
should be stated (for each such study).
If applicable, describe how any studies for which IPD were not available were dealt with. This should
include whether, how, and what aggregate data were sought or extracted from study reports and
publications (such as extracting data independently in duplicate) and any processes for obtaining and
confirming these data with investigators.
Data items 11 Describe how the information and variables to be collected were chosen. List and define all study-level
and participant-level data that were sought, including baseline and follow-up information. If
applicable, describe methods of standardizing or translating variables within the IPD data sets to
ensure common scales or measurements across studies.
IPD integrity A1 Describe what aspects of IPD were subject to data checking (such as sequence generation, data
consistency and completeness, baseline imbalance) and how this was done.
Risk of bias assessment
in individual studies
12 Describe methods used to assess risk of bias in the individual studies and whether this was applied
separately for each outcome. If applicable, describe how findings of IPD checking were used to inform
the assessment. Report if and how risk of bias assessment was used in any data synthesis.
Specification of
outcomes and effect
measures
13 State all treatment comparisons of interest. State all outcomes addressed and define them in detail.
State whether they were prespecified for the review and, if applicable, whether they were
primary/main or secondary/additional outcomes. Give the principal measures of effect (such as risk
ratio, hazard ratio, difference in means) used for each outcome.
(continued)
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Table. PRISMA-IPD Checklist of Items to IncludeWhen Reporting a Systematic Review andMeta-analysis of Individual Participant Data (IPD)a
(continued)
PRISMA-IPD
Section/Topic
Item
No.b Checklist Item Reported on Page
Synthesis methods 14 Describe the meta-analysis methods used to synthesize IPD. Specify any statistical methods and models
used. Issues should include (but are not restricted to):
• Use of a 1-stage or 2-stage approach
• How effect estimates were generated separately within each study and combined across studies
(where applicable)
• Specification of 1-stage models (where applicable) including how clustering of patients within studies
was accounted for
• Use of fixed- or random-effects models and any other model assumptions, such as proportional hazards
• How (summary) survival curves were generated (where applicable)
• Methods for quantifying statistical heterogeneity (such as I2 and τ2)
• How studies providing IPD and not providing IPD were analyzed together (where applicable)
• How missing data within the IPD were dealt with (where applicable)
Exploration of variation
in effects
A2 If applicable, describe any methods used to explore variation in effects by study- or participant-level
characteristics (such as estimation of interactions between effect and covariates). State all
participant-level characteristics that were analyzed as potential effect modifiers and whether these
were prespecified.
Risk of bias across
studies
15 Specify any assessment of risk of bias relating to the accumulated body of evidence, including any
pertaining to not obtaining IPD for particular studies, outcomes, or other variables.
Additional analyses 16 Describe methods of any additional analyses, including sensitivity analyses. State which of these were
prespecified.
Results
Study selection and IPD
obtained
17 Give numbers of studies screened, assessed for eligibility, and included in the systematic review with
reasons for exclusions at each stage. Indicate the number of studies and participants for which IPD
were sought and for which IPD were obtained. For those studies for which IPD were not available, give
the numbers of studies and participants for which aggregate data were available. Report reasons for
nonavailability of IPD. Include a flow diagram.
Study characteristics 18 For each study, present information on key study and participant characteristics (such as description of
interventions, numbers of participants, demographic data, unavailability of outcomes, funding source,
and if applicable duration of follow-up). Provide (main) citations for each study. Where applicable, also
report similar study characteristics for any studies not providing IPD.
IPD integrity A3 Report any important issues identified in checking IPD or state that there were none.
Risk of bias within
studies
19 Present data on risk of bias assessments. If applicable, describe whether data checking led to the
up-weighting or down-weighting of these assessments. Consider how any potential bias affects
the robustness of meta-analysis conclusions.
Results of individual
studies
20 For each comparison and for each main outcome (benefit or harm), for each individual study report the
number of eligible participants for which data were obtained and show simple summary data for each
intervention group (including, where applicable, the number of events), effect estimates, and
confidence intervals. These may be tabulated or included on a forest plot.
Results of syntheses 21 Present summary effects for each meta-analysis undertaken, including confidence intervals and
measures of statistical heterogeneity. State whether the analysis was prespecified, report the numbers
of studies and participants and, where applicable, report the number of events on which it is based.
When exploring variation in effects due to patient or study characteristics, present summary
interaction estimates for each characteristic examined, including confidence intervals and measures
of statistical heterogeneity. State whether the analysis was prespecified. State whether any interaction
is consistent across trials.
Provide a description of the direction and size of effect in terms meaningful to those who would put
findings into practice.
Risk of bias across
studies
22 Present results of any assessment of risk of bias relating to the accumulated body of evidence,
including any pertaining to the availability and representativeness of available studies, outcomes,
or other variables.
Additional analyses 23 Give results of any additional analyses (eg, sensitivity analyses). If applicable, this should also include
any analyses that incorporate aggregate data for studies that do not have IPD. If applicable, summarize
the main meta-analysis results following the inclusion or exclusion of studies for which IPD were not
available.
Discussion
Summary of evidence 24 Summarize the main findings, including the strength of evidence for each main outcome.
Strengths and
limitations
25 Discuss any important strengths and limitations of the evidence, including the benefits of access to IPD
and any limitations arising from IPD that were not available.
Conclusions 26 Provide a general interpretation of the findings in the context of other evidence.
Implications A4 Consider relevance to key groups (such as policy makers, service providers, and service users).
Consider implications for future research.
Funding
Funding 27 Describe sources of funding and other support (such as supply of IPD) and the role in the systematic
review of those providing such support.
Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.
a Reproduced with permission of the PRISMA-IPD Group, which encourages
sharing and reuse.
bA1-A3 denote new items that are additional to standard PRISMA items. A4 has
been created as a result of rearranging content of the standard PRISMA
Statement to suit the way that systematic reviews andmeta-analyses of IPD
are reported.
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Discussion
Systematic reviewsandmeta-analysesof individualparticipantdata
have been recognized as a gold standard approach from the early
daysofsystematic review.5,6Theyoffermanyadvantagesoveranaly-
ses that use aggregate data extracted from publications.4,7 These
include the potential to avoid bias arising from the absence of un-
publishedstudies andunreportedoutcomes,7,8 checkingand trans-
forming data to common scores or measures and standardizing
analysesacross studies,7 and thepossibilityofhandlingmissingdata
within studiesmoreappropriately.9 Individual-level informationen-
ables more flexible and robust analyses than are possible with ag-
gregate study results, including theability todeal appropriatelywith
time-to-eventand longitudinaldata. IPDmeta-analysesalsomayen-
hance evidence synthesismorewidely; for example, theymayhelp
quantify potentially causal associations from multiple observa-
tional studies9 or develop risk predictionmodels.10,11
With an established history in reviews of interventions in
cancer12andcardiovasculardisease,13 the IPDapproach isbeingused
increasingly4 and across a broadening range of health care areas.
However, it represents a minority of the systematic reviews
undertaken,3,4 perhaps owing to the time and resources required
tobuildcollaborationsof study investigators tosharedataandagree
on analyses to be performed. If IPD becomes more readily avail-
ableasa resultof current initiativesaiming tomakeprovisionofclini-
cal trial data for research purposes a legal, regulatory, or ethical
requirement,14,15 it is likely that in the future more systematic re-
views will access and analyze IPD. This will likely include synthesis
of IPD released in controversial areas where transparent, com-
plete, and high-quality reporting is essential.
As with all areas of research, systematic reviews and meta-
analysesof IPDcouldbebetter reported,16making it easier for read-
ers to understand, critique, and implement findings. Standard
PRISMAguidelines are geared toward systematic reviewsbasedon
aggregate data and so lack reference to some important aspects of
the IPDapproach. ThePRISMA-IPDextensionwas therefore devel-
oped to provide a framework for full and transparent reporting of
methodsused in the collection, checking, andmeta-analysis of IPD.
MainModifications to the PRISMA Checklist
Structured Abstract
Based on the PRISMA extension for abstracts17 tailored to the IPD
approach, a structured abstract (item 2) should include important
details of methods and results. Although journal format and word
limits may make it difficult to include all the outlined information,
as much relevant information as possible should be succinctly
summarized.
Figure. PRISMA-IPD FlowDiagram
No. Eligible studies for which IPD were
not sought (give reasons)
No. Studies excluded (give reasons)
No. Studies identified through database searching No. Studies identified through other sources,
including contact with researchers
IPD (report for each main outcome)
No. Studies included in analysis
No. Participants included in analysis
No. Participants excluded (give reasons)
Aggregate Data (report for each main outcome)
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No. Studies for which IPD were sought
No. Studies screened for eligibility
No. Studies after duplicates removed
No. Studies for which IPD were provided
No. Participants for whom data were provided
No. Participants for whom no data were
provided (give reasons)
No. Studies for which IPD were not provided
(give reasons)
No. Participants
No. Studies for which aggregate data
were available
No. Participants
IPD indicates individual patient data;
PRISMA, Preferred Reporting Items
for Systematic Reviews and
Meta-Analyses. Reproduced with
permission of the PRISMA-IPD Group,
which encourages sharing and reuse.
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Rationale
It may be useful to explain briefly the benefits that the IPD ap-
proach brings to the review, as well as the specific rationale for the
research question being addressed (item 3). This may highlight in-
adequaciesofanyexistingsystematic reviewsofaggregatedataand
may be particularly important in areas inwhich the approach is not
yet well established and the target audience is not familiar with its
strengths. Providing such information may also be helpful in per-
suading readers of the robustness and consequent value of find-
ings,whichmayhelpencourage their uptakeanduse inpractice, in-
cludingwithin clinical guidelines.18 For clarity, it is alwayshelpful for
reviews that updateor build onpreviously published reviews to ex-
plicitly make the link with prior versions.
Protocols and Registration
Access to IPD both permits more flexible and powerful analysis and
provides an opportunity for data manipulation. Thus, the produc-
tionof, andadherence to, aprotocol that includes adetailed analysis
plan is perhaps evenmore important than for a standard systematic
review. Deviation from the planned analyses may be necessary and
may even improve onwhatwas intended. However, transparency is
important, for example in statingwhich reported analyseswerepre-
plannedandwhichwereprimaryandsecondaryoutcomes.Suchstate-
mentscanbesupportedby referral to theprotocol.Becausesystem-
atic review protocols are increasingly being registered (eg, in
PROSPERO [http://www.crd.york.ac.uk/PROSPERO/]) and pub-
lished formally, a recommendation to includeacitationor link to reg-
istrationrecordsandformalpublishedprotocolshasbeenadded(item
5). It also may be helpful to include a copy of the protocol and data
request forms as an appendix to the published report.
Eligibility Criteria
Inclusion criteria are generally developed as for a standard system-
atic review.However, the IPD approachprovides an opportunity to
use only a subset of the enrolled population within a study. For ex-
ample, in a reviewofpediatric research interventions itmaybepos-
sible to include the IPD from just thechildrenenrolled ina study that
recruited both adults and children. Where any such additional in-
clusion/exclusion criteria are applied at the participant level, they
should be reported (item 6). As well as ensuring transparency, do-
ing so helps readers avoid confusion if the number of included par-
ticipants differsmarkedly from the number reported in the original
study publication.
Identifying Studies andObtaining Data
Direct contact and collaboration with study investigators, includ-
ing enlisting their help in identifying eligible studies, is a key feature
of systematic reviews andmeta-analyses of IPD. Item 7was there-
fore extended to include additional means of identifying studies.
These can be particularly important for identifying data not pub-
lishedat the timeof the systematic review. Item17has alsobeenex-
tended to include additional information on seeking IPD from the
original studies.
Data Collection, Harmonization, and Checking
Dataextractiondoesnotusuallyapply to thosestudies forwhich IPD
are obtained. The checklist therefore includes a new element un-
derdata collectionprocesses (item10) tocapturehow IPDwereob-
tained andmanaged, and item 11 now includes reporting themeth-
odsof standardizingor redefining the IPD received.19New itemson
methodsof exploringdata integrity (itemA1) and reportingdata in-
tegrity (item A3) have also been added, reflecting the importance
ofdata checkingandcorrectingany inaccuraciesor errors in the IPD
supplied.
Risk of Bias Assessment
Risk of bias assessments for included studies (item 12) and presen-
tation of findings (item 19) have been extended to consider direct
investigation of the IPD. For example, there might be less concern
about potential bias associated with envelope randomization if
checking the IPD shows that treatment allocation to study groups
is balanced over time, provides reassurance that envelopes have
been used in the planned sequence with none discarded, and that
there are no important imbalances in patient characteristics across
allocationgroups. Conversely, itmaybenecessary tohighlight con-
cerns revealed only by the IPD. For example, if checking IPD ran-
domization sequence reveals analternatingpatternof allocation for
a trial that reported apparently sound methods of randomization,
thisshouldbenoted.Obtainingthefull studyprotocolanddirectcon-
tactwith the participating study investigators alsomayprovide ad-
ditional information to inform assessment of risk of bias.
Handling Trials forWhich IPDWere Unavailable
An important aspect of validity is the completeness and represen-
tativeness of the data collected. It is therefore important to pro-
vide information on the numbers of studies and participants for
which IPD were sought and obtained (item 17), to report whether
there is potential risk of bias associated with nonavailability of IPD
(items 15 and 22), and to compare results from analyses that in-
cludeandexcludestudies forwhich IPDwerenotavailable (item23).
For the latter, 1-stage and 2-stagemeta-analysismodels (discussed
below)canbeusedtocombineaggregatedata (fromstudiesnotpro-
viding IPD) with the available IPD,20 and both sources of evidence
can be distinctly displayed on forest and funnel plots.16 This allows
the effect of non-IPD studies on meta-analysis conclusions to be
quantified and transparently displayed.
Synthesis Methods
IPD enablesmore flexible and potentiallymore powerful statistical
analyses thanarepossiblewithaggregatedata.However, it alsocre-
ates potential for “data dredging,” whereby reviewers explore nu-
merous outcomes and subgroups to find those that yield interest-
ing results. This made it important to add a recommendation to
report all outcomes analyzed and whether these were prespeci-
fied (item 13) and to record all subgroup analyses conducted and
whether these were prespecified (item A2).
Methods of synthesis are not always reported fully or well.3,4
Item 14has been extended to list aspects that should be addressed
in analyses of clinical trial data. A variety of analytic models can be
used including (1) those that first generate estimates of effective-
ness (aggregate data) for each study separately and then combine
these summary statistics using standard meta-analysis methods
(commonly termed a 2-stage approach), and (2) those that esti-
mate the overall meta-analytic effect from all data in all studies si-
multaneously (commonly termed a 1-stage approach). If a 1-stage
modeling approach is used, it is important that the clustering of pa-
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tients within studies is taken into account and that the data set is
not analyzed simplistically as a single “mega trial.”21 Care should be
taken to ensure that the model selection process is described ad-
equately and that full specifications areprovided.Results shouldbe
presentedwith a nonstatistical audience inmind. For example, co-
efficients from a 1-stage logistic or Cox regressionmodel relate to a
log odds ratio or a log hazard ratio, respectively; converting and re-
porting these as odds ratios or hazard ratios makes them easier to
understand.
It may be helpful to present results as both relative and abso-
lutedifferences (whichdependsonrelativedifferencesandonbase-
linerisk)between, forexample, interventions fromrandomizedtrials.
A large relative benefit may be of little practical importance if the
underlying risk and hence absolute improvement is small. Further-
more, because baseline event rates can differ substantially be-
tween different types of individual, the same relative effect may
translate to different absolute improvements, evenwhen the rela-
tive effect of intervention is the same. It therefore canbehelpful to
present information on relative and absolute differences accord-
ing to a series of differing baseline risks.22,23
Forestplotsenable readers toexaminecombinedestimates, in-
consistency across studies, and the precision of individual studies.
In commonwith the standardPRISMAStatement thedisplayof for-
est plots for key outcomes is advocated, irrespective of the type of
approach to statistical analysis.
Exploration of Effectiveness in Different Participant Types
A major motivation for adopting the IPD approach is the ability to
explore between-study heterogeneity and participant-level varia-
tion in treatment response. The latter is particularly important, as
it allows analyses to explorewhether there are any particular types
(subgroups) of participants who benefit differentially from the in-
tervention under investigation.24 This is reflected through an addi-
tional element in stating objectives (item 4) relating to presenta-
tion of subgroup hypotheses, a new item (item A2) to describe
methods, and an additional element relating to presenting results
(item 21). When reporting such analyses it is vital to state whether
there is any clear statistical evidence of a difference in outcome by
participant characteristics.Aswell asbeingof clinical relevance, any
such variationmay explain heterogeneity in results between trials.
PRISMA-IPD Amendments Relevant to All Systematic Reviews
Some PRISMA-IPD additions are relevant to all systematic reviews.
These include statement of any subgroup hypotheses (item 4); ci-
tationof publishedprotocols (item5); descriptionof how the infor-
mation to be collected (or extracted) was chosen (item 11); state-
mentofall comparisonsandoutcomesaddressedandwhether these
were primary outcomes (item 13); statement of whether analyses
were prespecified (items 13, 16, and 21); reporting of the number of
participants for which data were available (item 17); and descrip-
tionof interventions (item 18). ThePRISMAgroupmaywish to con-
sider some of these for inclusion in future versions of the standard
PRISMA Statement.
Implementation
PRISMA-IPDis intendedtoapplyto IPDmeta-analysisprimarilywithin
thecontextof systematic reviewof randomizedtrials. Ithasbeende-
veloped largely fromexperienceofundertaking reviewsof studiesof
the effects of health care interventions,where the approachwas es-
tablished in the late 1980s.25,26 Most examples are drawn from this
literature, and it is anticipated that the checklist will be usedmainly
in thiscontext.However,much isalso relevant tootherareas inwhich
IPD synthesis is gaining popularity, including systematic reviews of
diagnostic,27 prognostic,10,28,29 observational,30,31 causal,32 or
animal33,34 studies. Although not designed specifically for prospec-
tivemeta-analyses, inwhichstudy investigatorsdecide inadvanceto
formally combine individual-level data fromeachof their studies in a
largermeta-analytic synthesis,35manychecklist itemswill apply. Be-
cause systematic reviews and meta-analyses of IPD are often sub-
stantial projects, itmaynot alwaysbepossible to address all items in
detail within journal articleword limits. In this case, further informa-
tion should bemade available as supplementarymaterial.
ThePRISMA-IPDchecklist shouldbe largelyself-explanatoryand
represents theminimum amount of information that should be re-
ported to provide a full and transparent account of how the review
wasconducted. Itwill sometimesbenecessary to include further in-
formation not covered by PRISMA-IPD items to deal with nonstan-
dard issues thatoccurredduring the reviewprocess andconveynu-
ancesof findings.Synthesesof studydesignsother thanrandomized
trialsmay require furtherordifferent information.Authors andpeer
reviewers are encouraged to use the checklist to improve report-
ingand journal editors to include it in their endorsementofPRISMA.
Limitations
Development of the PRISMA-IPD Statement (as for the standard
PRISMAStatement)wasevidence-basedwherepossibleandwasoth-
erwise based on opinions gathered from persons with relevant ex-
pertise and experience. Response to the survey was limited (53 re-
spondents [28% response rate]). This may reflect it being open for
only a short time (necessitated by a fixed workshop date) as well as
its specialist focus. However, as its stated purpose was to provide a
startingpoint fordiscussionat theworkshop, this is not considereda
major limitation. The checklist has not been formally evaluatedprior
to proposed implementation. Whether use of PRISMA-IPD will im-
prove reporting quality requires evaluation in future research.
Conclusions
PRISMA-IPDprovidesguidelines for reportingsystematic reviewsand
meta-analysesof IPD.Futureresearchisneededtodeterminewhether
thisapproachwill lead to improvedreportingof this typeof research.
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